Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits

Laitinen, Kirsi; Laurila, Aino; Pyhälä, Liisa; Leinonen, Maija; Saikku, Pekka

doi:10.1128/iai.65.11.4832-4835.1997

Cited by 204 publications

(56 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other micro-organism infections, including Chlamydia pneumonia are reported to induce aortic inflammation. 80,81 Vascular involvement was not reported in IL-12B deficient mice, 82 but the antiangiogenic effect of IL-12 is widely reported. 83,84 IL-12-expressing tumor cells show low metastasis ability.…”

Section: Animal Modelsmentioning

confidence: 99%

Recent advances in Takayasu arteritis

2014

View full text Add to dashboard Cite

Takayasu arteritis (TAK) is a relatively rare systemic vasculitis mainly affecting the aorta and its large branches. While patients with TAK are more frequently observed in Asian countries, we can find patients with TAK all over the world. This limited number of patients has made it difficult to collect large numbers of patients and perform detailed studies. However, recent progresses have led to the identification of susceptibility genes and novel susceptibility human leukocyte antigen (HLA) alleles as well as accumulation of clues for the pathophysiology of TAK. IL12B was shown to be a susceptibility gene beyond ethnicity. MLX and FCGR2A/3A were shown to be associated with TAK in Japanese and Turkish/American populations, respectively. HLA-B*52:01 and *67:01 are susceptibility alleles to TAK, and the 171st and 67th amino acid residues of HLA-B protein are suggested important for TAK susceptibility. HLA-DQB1/DRB1 is recently reported as an independent susceptibility locus. Although there are no standardized serum markers or composite measures for disease activity of TAK, Japanese and Italian groups showed pentraxin 3 as a novel biomarker for detecting and monitoring patients with TAK. Recently, an Indian group proposed a novel scoring system called ITAS to evaluate disease activity of TAK. Standardization of assessing disease activity would lead to clinical studies with high quality. Several groups reported results of treatment for refractory TAK with biological agents targeting tumor necrosis factor or interleukin-6R. The recent accumulation of research data should improve understanding of the basic pathophysiology of TAK and lead to better management of patients with TAK.

show abstract

Section: Animal Modelsmentioning

confidence: 99%

Recent advances in Takayasu arteritis

2014

View full text Add to dashboard Cite

show abstract

“…Initially, seroepidemiological evidence indicated an association between CP and atherosclerosis and, subsequently, this intracellular pathogen was detected in atherosclerotic lesions [139,[153][154][155][156][157][158][159][160] and ruptured plaques [161]. Accordingly, CP was proposed to play a role in the pathogenesis of vascular disease, possibly by inducing a low-grade inflammation in the arterial wall [162][163][164][165][166], and there was great hope that antibiotic treatment might prevent acute cardiac problems in patients with coronary artery disease (CAD). However, although initial pilot studies in humans and experimental animal models appeared promising [167], a number of extensive clinical studies employing antibiotics for the primary or secondary prevention of coronary heart disease have failed to provide adequate evidence for the efficacy of such treatment (reviewed in [168]).…”

Section: Hcmv Infection In Patients With Vascular Diseasesmentioning

confidence: 99%

Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?

Söderberg‐Nauclér¹

2006

Journal of Internal Medicine

295

266

View full text Add to dashboard Cite

show abstract

“…In a variety of animal experimental models, repeated infection with C. pneumoniae through the respiratory tract demonstrates induction of early atherosclerotic lesions or accelerated progression of atherosclerosis in the aorta [52][53][54]. Studies in both rabbits and mice have demonstrated a potential interaction between infection with C. pneumoniae and elevated serum lipids resulting from dietary and/or genetic factors [55][56][57][58][59].…”

Section: I R E C T I S O L a T I O N O F C P N E U M O N I A E I mentioning

confidence: 99%

Chlamydia pneumoniae and atherosclerosis – what we know and what we don't

Ngeh

Anand

Gupta

2002

Clinical Microbiology and Infection

View full text Add to dashboard Cite

The clinical manifestations of atherosclerosis include coronary artery disease (CAD), stroke, abdominal aortic aneurysm and peripheral vascular disease. World-wide, CAD and stroke are the leading causes of death and disability. The recognition of atherosclerosis as an inflammatory disease in its genesis, progression and ultimate clinical manifestations has created an interesting area of vascular research. Apart from those well-known traditional risk factors for atherosclerosis, novel and potentially treatable atherosclerotic risk factors such as homocysteine (an amino acid derived from the metabolism of dietary methionine that induces vascular endothelial dysfunction) and infections have emerged. In fact, the century-old 'infectious' hypothesis of atherosclerosis has implicated a number of micro-organisms that may act as contributing inflammatory stimuli. Although cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae are the three micro-organisms most extensively studied, this review will focus on C. pneumoniae. Collaborative efforts from many disciplines have resulted in the accumulation of evidence from seroepidemiological, pathological, animal model, immunological and antibiotic intervention studies, linking C. pneumoniae with atherosclerosis. Seroepidemiological observations provide circumstantial evidence, which is weak in most prospective studies. Pathological studies have demonstrated the preferential existence of C. pneumoniae in atherosclerotic plaque tissues, while animal model experiments have shown the induction of atherosclerosis by C. pneumoniae. Finally, immunological processes whereby C. pneumoniae could participate in key atherogenic and atherothrombotic events have also been identified. Although benefits of the secondary prevention of atherosclerosis have been demonstrated in some antibiotic intervention studies, a number of negative studies have also emerged. The results of the ongoing large prospective human antibiotic intervention trials may help to finally establish if there is a causal link between C. pneumoniae infection and atherosclerosis.

show abstract

Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits

Cited by 204 publications

References 38 publications

Recent advances in Takayasu arteritis

Recent advances in Takayasu arteritis

Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?

Chlamydia pneumoniae and atherosclerosis – what we know and what we don't

Contact Info

Product

Resources

About